What version of Camatinib Lucius is?

Capmatinib (Capmatinib) is a targeted drug targeting specific gene mutations. It is mainly used to treat non-small cell lung cancer (NSCLC) with MET gene amplification or MET mutation-positive disease. Lucius Pharmaceutical Factory is a common manufacturer in Laos. The Laos Lucius version of capmatinib is a generic drug and is relatively cheap. The ingredients of the drugs produced may be similar to the original drug of capmatinib. It should also be noted that there may be certain uncertainties in its quality and safety.

Before choosing to use the Laos version of Capmatinib, patients and doctors should conduct a detailed understanding and evaluation of it, and ensure that it is purchased through formal channels to ensure the quality and safety of the drug. The common specification of drugs is 200mg*56 tablets, and the price per box is only more than 3,000 yuan. This price may also change due to exchange rate fluctuations, but compared with the original drug, its price is more advantageous, reducing the financial burden on patients.

In clinical application, the main indications for capmatinib are patients with locally advanced or metastatic non-small cell lung cancer who have received at least one systemic therapy, especially those who have been confirmed by genetic testing to have MET mutations or amplifications. The effectiveness and safety of the drug have been verified in multiple clinical trials, showing good therapeutic effects and tolerability.

According to current treatment guidelines, capmatinib is usually administered in oral form, and the recommended initial dose is400 mg twice daily. This method of administration makes it easier for patients to take it at home, improving treatment compliance. At the same time, it is also very important to monitor the patient's liver function and blood routine, because certain side effects may affect these indicators.